User menu

Docetaxel rechallenge in patients with metastatic castration-resistant prostate cancer

Bibliographic reference Oudard, Stephane ; Kramer, Gero ; Caffo, Orazio ; Creppy, L ; Loriot, Yohann ; et. al. Docetaxel rechallenge in patients with metastatic castration-resistant prostate cancer. In: B J U International, Vol. 115, no. 5, p. 744-752 (2015)
Permanent URL http://hdl.handle.net/2078.1/147211
  1. Tannock Ian F., de Wit Ronald, Berry William R., Horti Jozsef, Pluzanska Anna, Chi Kim N., Oudard Stephane, Théodore Christine, James Nicholas D., Turesson Ingela, Rosenthal Mark A., Eisenberger Mario A., Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer, 10.1056/nejmoa040720
  2. Petrylak Daniel P., Tangen Catherine M., Hussain Maha H.A., Lara Primo N., Jones Jeffrey A., Taplin Mary Ellen, Burch Patrick A., Berry Donna, Moinpour Carol, Kohli Manish, Benson Mitchell C., Small Eric J., Raghavan Derek, Crawford E. David, Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer, 10.1056/nejmoa041318
  3. Berthold Dominik R., Pond Gregory R., Soban Freidele, de Wit Ronald, Eisenberger Mario, Tannock Ian F., Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study, 10.1200/jco.2007.12.4008
  4. Berthold D. R., Pond G. R., de Wit R., Eisenberger M., Tannock I. F., , Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa, 10.1093/annonc/mdn288
  5. Oudard Stéphane, Banu Eugeniu, Beuzeboc Philippe, Voog Eric, Dourthe Louis Marie, Hardy-Bessard Anne Claire, Linassier Claude, Scotté Florian, Banu Adela, Coscas Yvan, Guinet François, Poupon Marie-France, Andrieu Jean-Marie, Multicenter Randomized Phase II Study of Two Schedules of Docetaxel, Estramustine, and Prednisone Versus Mitoxantrone Plus Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer, 10.1200/jco.2005.12.187
  6. Horwich A., Hugosson J., de Reijke T., Wiegel T., Fizazi K., Kataja V., Parker C., Bellmunt J., Berthold D., Bill-Axelson A., Carlsson S., Daugaard G., De Meerleer G., de Reijke T., Dearnaley D., Fizazi K., Fonteyne V., Gillessen S., Heinrich D., Horwich A., Hugosson J., Kataja V., Kwiatkowski M., Nilsson S., Padhani A., Papandreou C., Parker C., Roobol M., Sella A., Valdagni R., Van der Kwast T., Verhagen P., Wiegel T., , Prostate cancer: ESMO Consensus Conference Guidelines 2012, 10.1093/annonc/mds624
  7. Heidenreich Axel, Bastian Patrick J., Bellmunt Joaquim, Bolla Michel, Joniau Steven, van der Kwast Theodor, Mason Malcolm, Matveev Vsevolod, Wiegel Thomas, Zattoni Filiberto, Mottet Nicolas, EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer, 10.1016/j.eururo.2013.11.002
  8. Cookson Michael S., Roth Bruce J., Dahm Philipp, Engstrom Christine, Freedland Stephen J., Hussain Maha, Lin Daniel W., Lowrance William T., Murad Mohammad Hassan, Oh William K., Penson David F., Kibel Adam S., Castration-Resistant Prostate Cancer: AUA Guideline, 10.1016/j.juro.2013.05.005
  9. de Bono Johann Sebastian, Oudard Stephane, Ozguroglu Mustafa, Hansen Steinbjørn, Machiels Jean-Pascal, Kocak Ivo, Gravis Gwenaëlle, Bodrogi Istvan, Mackenzie Mary J, Shen Liji, Roessner Martin, Gupta Sunil, Sartor A Oliver, Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, 10.1016/s0140-6736(10)61389-x
  10. Scher Howard I., Fizazi Karim, Saad Fred, Taplin Mary-Ellen, Sternberg Cora N., Miller Kurt, de Wit Ronald, Mulders Peter, Chi Kim N., Shore Neal D., Armstrong Andrew J., Flaig Thomas W., Fléchon Aude, Mainwaring Paul, Fleming Mark, Hainsworth John D., Hirmand Mohammad, Selby Bryan, Seely Lynn, de Bono Johann S., Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy, 10.1056/nejmoa1207506
  11. Fizazi Karim, Scher Howard I, Molina Arturo, Logothetis Christopher J, Chi Kim N, Jones Robert J, Staffurth John N, North Scott, Vogelzang Nicholas J, Saad Fred, Mainwaring Paul, Harland Stephen, Goodman Oscar B, Sternberg Cora N, Li Jin Hui, Kheoh Thian, Haqq Christopher M, de Bono Johann S, Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study, 10.1016/s1470-2045(12)70379-0
  12. Parker C., Nilsson S., Heinrich D., Helle S.I., O'Sullivan J.M., Fosså S.D., Chodacki A., Wiechno P., Logue J., Seke M., Widmark A., Johannessen D.C., Hoskin P., Bottomley D., James N.D., Solberg A., Syndikus I., Kliment J., Wedel S., Boehmer S., Dall'Oglio M., Franzén L., Coleman R., Vogelzang N.J., O'Bryan-Tear C.G., Staudacher K., Garcia-Vargas J., Shan M., Bruland Ø.S., Sartor O., Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer, 10.1056/nejmoa1213755
  13. Kantoff Philip W., Higano Celestia S., Shore Neal D., Berger E. Roy, Small Eric J., Penson David F., Redfern Charles H., Ferrari Anna C., Dreicer Robert, Sims Robert B., Xu Yi, Frohlich Mark W., Schellhammer Paul F., Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer, 10.1056/nejmoa1001294
  14. Tannock, J Clin Oncol, 14, 1756 (1996)
  15. Beer, Br J Cancer, 91, 1425 (2004)
  16. Beer Tomasz M., Ryan Christopher W., Venner Peter M., Petrylak Daniel P., Chatta Gurkamal S., Ruether J. Dean, Chi Kim N., Young James, Henner W. David, , Intermittent chemotherapy in patients with metastatic androgen-independent prostate cancer : Results from ASCENT, a double-blinded, randomized comparison of high-dose calcitriol plus docetaxel with placebo plus docetaxel, 10.1002/cncr.23163
  17. Ansari, Oncol Rep, 20, 891 (2008)
  18. Soga Norihito, Kato Manabu, Nishikawa Kouhei, Hasegawa Yoshihiro, Yamada Yasushi, Kise Hideaki, Arima Kiminobu, Sugimura Yoshiki, Intermittent docetaxel therapy with estramustine for hormone-refractory prostate cancer in Japanese patients, 10.1007/s10147-008-0814-y
  19. Eymard Jean-Christophe, Oudard Stéphane, Gravis Gwenaelle, Ferrero Jean-Marc, Theodore Christine, Joly Florence, Priou Frank, Krakowski Ivan, Zannetti Alain, Thill Laurence, Beuzeboc Philippe, Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study : DOCETAXEL REINTRODUCTION IN PATIENTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, 10.1111/j.1464-410x.2010.09296.x
  20. Di Lorenzo Giuseppe, Buonerba Carlo, Faiella Adriana, Rescigno Pasquale, Rizzo Mimma, Autorino Riccardo, Perdonà Sisto, Riccardi Nando, Scagliorini Sarah, Scognamiglio Florinda, Masala Daniele, Ferro Matteo, Palmieri Giovannella, Aieta Michele, Marinelli Alfredo, Altieri Vincenzo, De Placido Sabino, Cartenì Giacomo, Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer : DOCETAXEL RE-TREATMENT IN CASTRATION-RESISTANT PROSTATE CANCER, 10.1111/j.1464-410x.2010.09498.x
  21. Loriot Yohann, Massard Christophe, Gross-Goupil Marine, Di Palma Mario, Escudier Bernard, Bossi Alberto, Chauchereau Anne, Fizazi Karim, The interval from the last cycle of docetaxel-based chemotherapy to progression is associated with the efficacy of subsequent docetaxel in patients with prostate cancer, 10.1016/j.ejca.2010.04.010
  22. Mountzios Ioannis, Bournakis Evangelos, Efstathiou Eleni, Varkaris Andreas, Wen Sijin, Chrisofos Michael, Deliveliotis Charalambos, Alamanis Christos, Anastasiou Ioannis, Constantinides Constantine, Karadimou Alexandra, Tsiatas Marinos, Papadimitriou Christos, Bamias Aristotelis, Dimopoulos Meletios A., Intermittent Docetaxel Chemotherapy in Patients With Castrate-resistant Prostate Cancer, 10.1016/j.urology.2010.08.044
  23. Caffo Orazio, Pappagallo Giovanni, Brugnara Sonia, Caldara Alessia, di Pasquale Maria Chiara, Ferro Antonella, Frisinghelli Michela, Murgia Viviana, Russo Lucianna Maria, Soini Barbara, Valduga Francesco, Veccia Antonello, Galligioni Enzo, Multiple Rechallenges for Castration-resistant Prostate Cancer Patients Responding to First-line Docetaxel: Assessment of Clinical Outcomes and Predictive Factors, 10.1016/j.urology.2011.11.043
  24. Schallier, Anticancer Res, 32, 633 (2012)
  25. Heck Matthias M., Thalgott Mark, Retz Margitta, Wolf Petra, Maurer Tobias, Nawroth Roman, Hatzichristodoulou Georgios, Gschwend Jürgen E., Kübler Hubert, Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer : DOCETAXEL RECHALLENGE IN METASTATIC CRPC, 10.1111/j.1464-410x.2012.11364.x
  26. Scher Howard I., Halabi Susan, Tannock Ian, Morris Michael, Sternberg Cora N., Carducci Michael A., Eisenberger Mario A., Higano Celestia, Bubley Glenn J., Dreicer Robert, Petrylak Daniel, Kantoff Philip, Basch Ethan, Kelly William Kevin, Figg William D., Small Eric J., Beer Tomasz M., Wilding George, Martin Alison, Hussain Maha, Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group, 10.1200/jco.2007.12.4487
  27. Seruga Bostjan, Ocana Alberto, Tannock Ian F., Drug resistance in metastatic castration-resistant prostate cancer, 10.1038/nrclinonc.2010.136
  28. Kuczynski Elizabeth A., Sargent Daniel J., Grothey Axel, Kerbel Robert S., Drug rechallenge and treatment beyond progression—implications for drug resistance, 10.1038/nrclinonc.2013.158
  29. Toulmonde M., Madranges N., Brouste V., Donamaria C., MacGrogan G., Durand M., Bonnefoi H., Mauriac L., Debled M., Docetaxel rechallenge after a first response in non-resistant metastatic breast cancer: significant activity with manageable toxicity, 10.1007/s10549-012-2060-2
  30. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial, 10.1016/s0140-6736(03)13718-x
  31. Zama Ivan N., Hutson Thomas E., Elson Paul, Cleary James M., Choueiri Toni K., Heng Daniel Y.C., Ramaiya Nikhil, Michaelson M. Dror, Garcia Jorge A., Knox Jennifer J., Escudier Bernard, Rini Brian I., Sunitinib rechallenge in metastatic renal cell carcinoma patients, 10.1002/cncr.25583
  32. Heidenreich Axel, Bracarda Sergio, Mason Malcolm, Ozen Haluk, Sengelov Lisa, Van Oort Inge, Papandreou Christos, Fossa Sophie, Hitier Simon, Climent Miguel Angel, Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: Results of the European compassionate-use programme, 10.1016/j.ejca.2014.01.006
  33. Gan L., Chen S., Wang Y., Watahiki A., Bohrer L., Sun Z., Wang Y., Huang H., Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate Cancer, 10.1158/0008-5472.can-09-1504
  34. Zhu M.-L., Horbinski C. M., Garzotto M., Qian D. Z., Beer T. M., Kyprianou N., Tubulin-Targeting Chemotherapy Impairs Androgen Receptor Activity in Prostate Cancer, 10.1158/0008-5472.can-10-0585
  35. Halabi Susan, Armstrong Andrew J., Sartor Oliver, de Bono Johann, Kaplan Ellen, Lin Chen-Yen, Solomon Nicole C., Small Eric J., Prostate-Specific Antigen Changes As Surrogate for Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer Treated With Second-Line Chemotherapy, 10.1200/jco.2013.50.3201
  36. Halabi S., Lin C.-Y., Small E. J., Armstrong A. J., Kaplan E. B., Petrylak D., Sternberg C. N., Shen L., Oudard S., de Bono J., Sartor O., Prognostic Model Predicting Metastatic Castration-Resistant Prostate Cancer Survival in Men Treated With Second-Line Chemotherapy, 10.1093/jnci/djt280
  37. Sweeney, J Clin Oncol, 32, LBA2 (2014)
  38. Ryan Charles J., Smith Matthew R., de Bono Johann S., Molina Arturo, Logothetis Christopher J., de Souza Paul, Fizazi Karim, Mainwaring Paul, Piulats Josep M., Ng Siobhan, Carles Joan, Mulders Peter F.A., Basch Ethan, Small Eric J., Saad Fred, Schrijvers Dirk, Van Poppel Hendrik, Mukherjee Som D., Suttmann Henrik, Gerritsen Winald R., Flaig Thomas W., George Daniel J., Yu Evan Y., Efstathiou Eleni, Pantuck Allan, Winquist Eric, Higano Celestia S., Taplin Mary-Ellen, Park Youn, Kheoh Thian, Griffin Thomas, Scher Howard I., Rathkopf Dana E., Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy, 10.1056/nejmoa1209096
  39. Beer Tomasz M., Armstrong Andrew J., Rathkopf Dana E., Loriot Yohann, Sternberg Cora N., Higano Celestia S., Iversen Peter, Bhattacharya Suman, Carles Joan, Chowdhury Simon, Davis Ian D., de Bono Johann S., Evans Christopher P., Fizazi Karim, Joshua Anthony M., Kim Choung-Soo, Kimura Go, Mainwaring Paul, Mansbach Harry, Miller Kurt, Noonberg Sarah B., Perabo Frank, Phung De, Saad Fred, Scher Howard I., Taplin Mary-Ellen, Venner Peter M., Tombal Bertrand, Enzalutamide in Metastatic Prostate Cancer before Chemotherapy, 10.1056/nejmoa1405095
  40. Mezynski J., Pezaro C., Bianchini D., Zivi A., Sandhu S., Thompson E., Hunt J., Sheridan E., Baikady B., Sarvadikar A., Maier G., Reid A. H. M., Mulick Cassidy A., Olmos D., Attard G., de Bono J., Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?, 10.1093/annonc/mds119
  41. Pezaro Carmel J., Omlin Aurelius G., Altavilla Amelia, Lorente David, Ferraldeschi Roberta, Bianchini Diletta, Dearnaley David, Parker Christopher, de Bono Johann S., Attard Gerhardt, Activity of Cabazitaxel in Castration-resistant Prostate Cancer Progressing After Docetaxel and Next-generation Endocrine Agents, 10.1016/j.eururo.2013.11.044
  42. Al Nakouzi Nader, Le Moulec Sylvestre, Albigès Laurence, Wang Chris, Beuzeboc Philippe, Gross-Goupil Marine, de La Motte Rouge Thibault, Guillot Aline, Gajda Dorota, Massard Christophe, Gleave Martin, Fizazi Karim, Loriot Yohann, Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies, 10.1016/j.eururo.2014.04.015